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Introduction
In providing permanent medications for the medical 
institutions the antibiotics present a particular permanent 
scientific and practical interest.  Numerous textbooks, legis-
lation and scientific research [1, 2, 3, 4] are dedicated to this 
subject.  In many countries a special attention is drawn to the 
qualitative analysis of the rotation of antibiotics (both in hos-
pitals and in outpatient medical institutions) used depending 
on the type of nosocomial infection, their consumption rate, 
the antibiotic subgroup used and the maximum limit of the 
systemic antimicrobial drug consumption [5, 6, 7].
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Abstract
The dynamics of the ratio between the consumption and stocks of antibiotics in a hospital pharmacy for the period of 2009-2012 is presented.  The 
defined daily dose (DDD) based on the data by the National Science and Practice Centre of Emergency Medicine is determined.  The resistance changes 
of pathogenic microbes causing nosocomial infections have been examined.  The activities realized in the mentioned directions have brought out in the 
decrease of the consumption and stock ratio from 1:0.74 in 2009 to 1:2.03 in 2012, reducing the DDD consumption of antibiotics per 1000 occupied bed/
days from 1118 to 840 grams or by 33.09%.  The months/risk coefficient in the pharmaceutical supply has decreased from 4.41 to 2.12 or by 2.08 times. 
Despite the lack of the program for processing and analyzing the condition of the pathogenic antimicrobial resistance, the general analysis has showed 
that the average resistance of gram-negative and gram-positive pathogenic microorganisms in 2012 in comparison with 2010 and 2011 decreased by 
16.8% and 13.58% respectively.  Has been proposed the optimization of the ratio of drugs reserves and their monthly consumption in pharmacies, that is 
a new criterion for assessing the quality of current provision with drugs – the risk factor in pharmaceutical provision in the medical institutions, based 
on the ratio between the monthly consumption and the stocks.  The measures based on the evaluation results to improve the planning, maintenance, 
insurance and the rational use of antibiotics and the quality of the study of the bacteriological tests database are proposed.
Key words: drug supplies, stocks, antibiotics, nosocomial infections, rational use, antibiotics resistance.
Динамика соотношения расхода и запаса антибиотиков в больницах
Е. Берназ
Реферат
Изучена динамика движения расхода и запасов антибиотиков, а также определена их средняя поддерживающая суточная доза (ПСД) в 
период 2009-2012 годов в Национальном Научно-Практическом Центре Ургентной Медицины.  Определена средняя резистентность патогенных 
грамположительных и грамотрицательных микроорганизмов на антибиотики.  Изучение состояния дел и своевременные действия в этом 
направлении понизили коэффициент соотношения между расходом и запасами антибиотоков с 1:0,74 в 2009 до 1:2,03 в 2012 году, уменьшив 
ПСД антибиотиков на одну тысячу койкодней с 1118 до 840 граммов или на 33,09%.  Коэффициент риска фармацевтического обеспечения 
уменьшился с 4,41 до 2,12 месяцев риска. Несмотря на отсутствие специальной программы по обработке данных о состоянии резистентности 
патогенных микроорганизмов, проведенный общий анализ показал, что их резистентность уменьшилась в 2012 г. по сравнению с 2010-
2011 гг. для грамположительных и грамотрицательных микроорганизмов на 16,8% и 13,58% соответственно.  Представлена аргументация 
предложений по разработке нормативных актов для оптимизации соотношения между месячным расходом и наличием неснижаемых 
минимальных и максимальных запасов в больничных аптеках.  Предложен еще один критерий определения качества бесперебойного 
обеспечения медикаментами – коэффициент риска фармацевтического обеспечения, являющийся соотношением между месячным расходом 
и наличием запасов.  На основании полученных данных предложены меры по оптимизации планирования, обеспечения и рационального 
расхода антибиотиков, а также улучшению качества изучения базы данных бактериологических анализов.
Ключевые слова: обеспечение лекарствами, запасы, антибиотики, внутрибольничные инфекции, рациональное использование, 
устойчивость к антибиотикам.
Nevertheless, the ratio between the consumption and 
stocks, as an important indicator of optimal rational use of 
drug remedies generally, and antimicrobial ones, in particular, 
is not studied enough and highlighted by scientific research 
literature.  This study is dedicated to the above theme and 
presents the analysis of gram-positive and gram-negative 
pathogenic microbial resistance to antibiotics as an important 
factor of qualitative treatment of the patients.  The evaluation 
was based upon the drugs consumption data collected for 
four years (2009-2012) by the National Science and Practice 
Centre of Emergency Medicine (NSPCEM).  The methods of 
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statistical, descriptive, mathematical, analytical and logical 
comparison were used.
The volume and spectrum of the antibiotics usage is 
dictated by the institution’s specialization which is fully 
represented in antimicrobial treatment argumentation.  The 
recent scientific research shows a direct relationship between 
the administered quantities of drugs and the resistance of 
pathogenic microorganisms depending, sometimes, on the 
seasonal temperature [8, 9].
The complete and dynamic analysis of the systemic an-
timicrobial remedies usage as well as the level of pathogenic 
microbes’ resistance to great extent contributes to the ratio-
nalization and optimization of the consumption of antibiotics, 
and, ultimately, positively influences the quality of treatment 
of the patients.
The results of the evaluations
Let us remember that the total cost of the consumption of 
the supply resources in the NSPCEM in 2012 was 28447000 
lei, of which 12130213 lei or 43% was spent on drugs gener-
ally, and the cost of the systemic antimicrobial remedies of 
the total amount of drugs was 1851036 lei or 15%.
The number of patients treated in the above institution 
was 20946 in 2009, 21341 in 2010, 19913 in 2011 and 20664 
in 2013.
All the used antimicrobial remedies were divided into 
the subgroups: aminopenicillins, cephalosporins (I, II and 
III generations), carbapenems, aminoglycosides (II and III 
generations), chinolons, lincosamides, tetracyclines, am-
fenicols, antifungals, antivirals and antiprotozoy.  After each 
year of 2009, 2010, 2011, 2012 the total amount of antibiotic 
consumption was calculated in grams and in lei according to 
the groups shown in the graphs below.
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Fig. 1.  The antimicrobal remedy usage chart for 2009–2012 
in lei/grams.
Figure 1 is a chart of antimicrobial remedies systemic 
consumption in grams and lei indices in the period of 2009-
2012.  As we can see, the cost of the consumption of antibi-
otics from aminopenicillins group decreased from 42019 lei 
(24148.9 grams) in 2009 to 2136 lei (1374 grams) in 2012; 
for the first generations of cephalosporins – from 366194 lei 
(116307 grams) in 2009 to 162819 lei (58664 grams) in 2012; 
for antifungials – from 40538 lei (270.1 grams) in 2009 to 
226 lei (26.7 grams) in 2012 etc.  On the contrary, the cost of 
the third-generation cephalosporins consumption increased 
from 291530 lei (27382.7 grams) in 2009 to 401151 lei (41940 
grams) in 2012, of carbapenems – from 155053 lei (4045.2 
grams) in 2009 to 430808 lei (14895 grams) in 2012, of chino-
lons – from 123964 lei (717 grams) in 2009 to 263541 lei (1523 
grams) in 2011.  These sums were due to the broad spectrum 
of expensive and very expensive prices for antibiotics.  In total 
to purchase the whole lot of systemic antimicrobial remedies 
only in 2009 1562575 lei (222878 grams) was spent and in 
2012 – 1837614 lei (169800 grams), what amounts to 275039 
more lei spent than in 2009 while for the total mass in grams a 
decrease in consumption of 53078 grams was registered.  Some 
medical institutions with a wide consumption of antibiotics 
use some of them for surgery purposes as well [10]. 
Despite the considerable decrease in the consumption of 
the generations of cephalosporins as it is showed in fig. 2 the 
wide administration of cephalosporins takes place.  For the 
evaluated period the total consumption cost of cephalosporin 
antibiotics was 801078 lei or 51.3% (167140 grams or 75%) in 
2009, 933844 lei or 40.2% (159792 grams or 77%) – in 2010, 
811839 lei or 41.5% (111384 grams or 70.5%) – in 2011, 665 
193 lei or 36.2% (105 950 grams or 62.4%) in 2012.
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Fig. 2. Activity of the antimicrobial groups of cephalosporins.
According to the characteristics of the antimicrobial activ-
ity of cephalosporin generations [11] and the resistance of the 
pathogenic microbes (the data are gained from the institution’s 
bacteriological laboratory) it is evident that the sudden switch 
to the cephalosporins III-G consumption in 2010 did not have 
a solid justification, especially keeping in mind that about 
70-80% of nosocomial surgical infections are caused by the 
gram-positive pathogenic microbes [12, 13].  In comparison 
with 2011 in 2012 already the consumption cost of the first 
generation cephalosporins rose from 116857 lei (37115 grams) 
to 185304 lei (59014 grams), what amounts to 158.57%.
To determine and compare the consumption of antibiotics 
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for the period of 2009-2012 the statistics data concerning the 
number of treated patients, with the exception of those who 
paid for the treatment, the number of bed/days and total an-
nual quantities of antibiotics were used.  Taking the above as 
a base the defined daily dose (DDD) was calculated for one 
thousand days [1, 15].  The final data are presented in table 1.
As shown in table 1, the consumption of antibiotics in 2011 
and 2012 decreased by 33.09% in comparison with 2009 and 
2010 and this happened due to the several measures taken to 
use rationally this group of drug remedies.  It is noteworthy 
that by the assessment of systemic antimicrobial remedies 
consumption in 530 hospitals in France, this ration is mini-
mum 62.3 grams and maximum – 557.7 grams as a DDD/1000 
daily occupied beds [17].
Table 2 shows the resistance in average percentage units 
of gram-negative and gram-positive microorganisms of bio-
Table 2
The average percent resistence of gram-negative and gram-positive microorganisms of biosubstrate 
in NSPCEM in 2010-2012
Drugs 
Year 2010 % Year 2011 % Year 2012 %
Gram - Gram + Gram - Gram + Gram - Gram +
Aminopenicillin
Ampicillinum 84.1 84.1 52.7 84.7 82.8
Cephalosporins Generation I
Cefazolinum 84 79.4 55.3 52.6 14.9
Cephalosporins Generation II
Cefuroximum 93.9 48.7 56.6 15.7
Cefuroximum (Cefatoxim) 65.3 48.7 66.1 48.7 36.1 15.7
Cephalosporins Generation III
Cefoperazonum 77.8 72.3 54.7 55 54.7
Ceftazidimum 89 70.9 47.6
Ceftazidimum (Fortum) 89 70.9 47.6
Ceftriaxonum 59.2 23.9 70.3 47.5 47.4 18.9
Generaţia IV
Cefepimum 82.6 75.2 50.7 24.3
Combinations of b-lactams with inhibitors b-lactamases: inhibitors of beta-lactamases
Amoxycillinum + Ac.
Clavulanicum 85.4 19.8 75.6 23.1 41.3 9.2
Aminoglycosides Generation II
Gentamicinum 47.4 11.6 58 20.4 48.6 17.1
Aminoglycosides Generation III
Amikacinum (Amicil) 40 6.9 38.9 7.6 33.1
Chinolons
Ciprofloxacinum 45.1 63 44.3 48.1 29.9
Gatifloxacinum 42.6 10.3 43.8 10.3 55.5
Lincosamides
Lincomycinum 43.6 42.3 26.5
Table 1
Defined Daily Dose for one thousand days (DDD/1000) in NSPCEM
Indicator Year 2009 2010 2011 2012
Discharged patients Number 20946 21341 19913 20664
Average duration of the treatment Days 8.62 8.62 8.66 8.82
The number of occupied bed/days Number 188762 191556 186246 199816
Antibiotics administration Grams 222878 207880 157937 169800
Consumption of antibiotics – DDD Grams 1.118 1.07 0.88 0.8
The average consumption of antibiotics – DDD/1000 Grams 1118 1080 840 840
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substrate in NSPCEM in 2010-2012.  From this presentation 
we can see that the average resistance of pathogenic gram-
negative microorganisms (Escherichia coli, Klebsiella oxytoca, 
Klebsiella pneumonia, Enterobacter aerogenes + Enterobacter 
cloacae, Proteus vulgaris + Proteus mirabilis, Pseudomonas 
aeruginosa, Acinetobacter, Morganella and Rettgerella) in 2012 
compared to 2010 and 2011 decreased for the cephalosporins 
on average by 25.7%, combinations of beta-lactams and beta-
lactamase inhibitors – by 32.2%, aminoglycosides – by 7.6% 
and chinolons – by 1.6%.
The average resistance of the gram-positive pathogenic 
microorganisms (Streptococcus pyogenes, Enterococci, Staphy-
lococcus aureus, Staphylococcus epidermidis) in 2012 compared 
to 2010 and 2011 decreased for the cephalosporins by 33.7%, 
combinations of beta-lactams inhibitors of beta-lactamases – 
by 13.3%, aminoglycosides – by 3.3%, chinolons – by 14.4% 
and linconsamides – by 15.8%.
The above presented data have a general character.  Un-
fortunately, the institution has not implemented a special pro-
gram to set a database, containing the results of the analyses 
on microbial resistance got from organic substrates collected 
from the patients.  In the absence of the above the margin of 
a possible error is still high.  Thus, to discover the new classes 
of antibiotics is still difficult.
In the last 30 years only two genuinely new classes of an-
tibiotics have come to the pharmaceutical market, and they 
are effective only for the treatment of the infections caused by 
gram-positive bacteria (oxazolidinones, cyclic lipopeptides) 
[18].
Figure 3 shows the antibiotics consumption data compared 
to the consumption data of the total amount of drugs in 2009, 
2010, 2011, 2012.
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Fig. 3.  The report of the annual consumption of antibiotics 
compared to the total annual amount of drugs.
In figure 3 we can see that the share of antibiotics in the 
overall consumption of medications increased by 2.2% in 2010 
compared to 2009, and during the periods of 2011 and 2012 
it had a gradual decrease and amounted to the sum of 487129 
lei or by 21% less than in 2010.
In accordance with the current regulations [19] the drugs 
providing quality must be optimal; the stock must be about 
twice as much as the consumption.  We also pay attention 
to the fact that the annual stock of antibiotics is calculated 
as their amount left after the end of each month of the year.
Figure 4 presents the data on the relationship between the 
consumption and the stock of systemic antimicrobials for the 
years of 2009, 2010, 2011, 2012.
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Fig. 4.  The consumption/stock report of antibiotics for the 
period of 2009-2012 (in lei).
Figure 4 shows that the relationship between stock and 
consumption was of 0.74:1 in 2009, 1.05:1 in 2010, 1.61:1 in 
2011 and 2.03:1 in 2012.  Therefore, the optimal ratio between 
stock and consumption was obtained only in 2012.  The con-
sumption gradually decreased by 367.877 lei in 2011 and by 
487.129 lei in 2012 in comparison with 2010.
The results of the monthly dynamic evaluation to maintain 
the ratio between the consumption and stock during the years 
2009, 2010, 2011, 2012 is shown in the figure below.
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Fig. 5.  The antibiotics consumption/stock report for the period 
of 2010-2012 (in lei).
The analysis of the monthly consumption of the systemic 
antimicrobials, shown in figure 5, demonstrates that dur-
ing nine months in 2009 and during 5 months in 2010 the 
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consumption was higher than the stock, which involves the 
likelihood of deficit of some antibiotics.  The situation was 
favourable in 2011 and 2012.  During this period the monthly 
consumption curves were lying under the stocks curves.  The 
analysis of the level of monthly consumption of antibiotics 
in comparison to their total annual stock (the amounts left 
after the end of each month of the year) shows that when the 
annual stock is 1.5 times higher than the consumption (fig. 
4), all monthly stocks are higher than the monthly consump-
tion as well.
An important direction in the achieving big progress in 
antimicrobial treatment is the study of the dependence of 
pathogenic microbes’ resistance on the seasonal temperature 
throughout the year.  The thorough analysis performed by 
American scientists in more than 300 hospitals in the US in 
the period of 1999-2007 showed that antibiotics are more used 
in cold seasons.  It can be noticed that in the colder months 
of the year (November, December, January, February, March 
and a part of April) the antibiotic consumption is, in most of 
the cases, more than in the other time of the year.
At the same time a thorough analysis, performed in over 
300 hospitals in the United States, in the period of 1999-2007, 
showed that antibiotics have a higher use in the cold season. 
Fig. 6 shows that the resistance of pathogenic microbes in the 
case of E. coli is much higher to aminopenicillins during cold 
and not hot period of the year [20].  Promoting the results of 
such important achievements and performing the research 
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Fig. 6.  Seasonal pattern - the antibiotic use depending 
on the strength of E. coli.
Table 3
Consumption/stock monthly report by pharmacotherapeutical groups
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in this direction will help improve the treatment, saving the 
remedies of systemic use antimicrobials, and make the orga-
nization of the use of antibiotics more efficient.
The analysis of the relationship between the consumption 
and stock subgroups and not the general group of antibiot-
ics demonstrates that the monthly consumption of these 
subgroups needs to be considered a definitive qualitative 
indicator.
Table 3 gives the recent data of the consumption/stock 
monthly report, according to pharmacotherapeutic subgroups 
of antibiotics.  The need for such an assessment is dictated 
by qualitative provision with medications, as well as by the 
fact that, according to the valid normative acts, the overall 
acquisition process of the drugs takes 35-45 days.  As shown in 
the table, we can see that the yearly medication consumption 
varied from one month to another, depending on the quality 
of the antibiotic subgroups supply.
During the evaluated period for 4 sub groups of antibi-
otics the monthly consumption was higher than the stocks 
during 10 months: for 1 sub group – within 9 months, in two 
sub-groups-within 8 months and so on.  The months/risk 
ratio is determined by the number of months where a higher 
consumption than the stock was registered for all subgroups, 
divided by the number (12) of months of the year.  For the 
period of 2009-2012 this coefficient decreased from 4.41 in 
2009 to 2.12 in 2012 or was 2.08 times as little (4.41:2.12).  It 
can be noticed that the lack of one or another medical remedy 
in the period of risk months is more likely, but not necessarily 
takes place, and is related to several factors, the main of which 
is the organization of the effective dynamics of providing 
supplies of drugs followed by the permanent analysis of the 
existing stock, according to the pharmacotherapeutical groups 
in the medical institution pharmacy.
Conclusions
1. The utilization spectrum of antibiotics for systemic use 
in NSPCEM includes 10 subgroups of antibiotics.  The total 
consumption cost in 2009 was 1562575 lei (222878 grams) and 
in 2012 it amounted to 1837614 lei (169800 grams).  In the 
period of 2009-2012 the consumption of antibiotics increased 
by 17.6%, which amounts to 275039 lei, and it decreased in 
mass by 23.81%, what makes up 53078 grams.
2. The DDD per one thousand occupied bed/days in the 
period of years 2009-2012 decreased from 1118 grams to 840 
grams or by 33.09%.
3. The most widely used antimicrobials are cephalosporins, 
which were registered as having the highest consumption cor-
responding to 801078 lei or 51.3% (167140 grams or 75%) in 
2009 with a gradual decrease to 665193 lei or 36.2% (105950 
grams or 62.4%) in 2012.
4. The consumption/stock ratio was reduced from 1:0.74 
in 2009, to 1:1.05 in 2010 and from 1:1.61 in 2011 to 1:2.03 in 
2012.  It can be noted that when the annual stock is 1.5 times 
as much as the consumption, the monthly stocks being less 
than the consumption were not registered.
5. We propose a new criterion, so-called months/risk coef-
ficient to assess the quality of medical remedies availability 
in the medical institutions, where a higher consumption 
than the stock for the antibiotic subgroups drugs, divided to 
12 (number of months of the year) was registered.  For the 
period of 2009-2012, according to the assessment, the coef-
ficient decreased from 4.41 to 2.12 or by 2.08 times (4.41:2.12).
6. The evaluation results of the analysis of biomaterial in 
institutional bacteriological laboratory demonstrated that, in 
comparison with 2012, the average resistance of gram-negative 
and gram-positive microorganisms decreased by 16.8% in 
2010 and by 13.58% – in 2011.  Therefore the margin of error 
remains high in the absence of a modern database and analysis 
program to evaluate the collected biomaterial analyses results.
7. The absence of analysis or a superficially made analysis 
of the dynamic ratio between the consumption and stock leads 
to the difficulties of the optimization of the current medica-
tions availability.  This situation allows us to assume that the 
months/risk coefficient of the pharmaceutical supply in other 
medical institutions in Moldova at present is the same as one 
recorded in NSPCEM for 2009-2010, that means that it is not 
less than for the period of 4 months.
8. A rational usage of antibiotics directly correlated with 
the resistance of pathogenic microbes, which, in turn, depends 
on the change of seasonal temperature during the year, does 
not have any scientific or practical base, as there are no any 
researches carried out in the medical institutions in the Re-
public of Moldova.
Suggestions
1. To ensure the presence and the continuous improvement 
of the results referred to in points 1, 2, 3 and 6 of the conclu-
sions, the author proposes to develop the project “On norms of 
the availability of stocks of antibiotics in medical institutions 
not less than 1.5 times as much and not more than twice as 
much in quantity in comparison with the average monthly 
consumption correlated with the DDD/1000 and submit it 
for the approval by the order of MSRM.
2. To introduce the pharmaceutical supply coefficient of 
months/risk as one of the basic criteria in assessing the quality 
of availability of drugs in the medical institutions.
3. To continue the evaluation of the origin of gram positive 
and gram negative pathogenic microbes resistance in order to 
ensure the quality of antimicrobial treatment and the organiza-
tion of the rational use of antibiotics in medical institutions:
a) to specify the data according to the medical departments,
b) to adopt the measures aimed to develop a statistic 
program for database and analysis of the collected bio-
substances showing the type of pathogenic microbes and 
the level of their resistance to antibiotics.
4. To organize the investigation regarding the rational 
consumption of antibiotics, based on the presented important 
scientific results about the sharp changes of the pathogenic 
microbes resistance, depending on the seasonal temperature, 
what implies the following starting points:
a) to study the scientific and practical achievements, con-
cerning the correlation between pathogenic microbes’ 
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resistance and the seasonal temperature in the countries 
having more scientific centers in this field,
b) to plan and realize several scientific studies in the 
NSPCEM that will demonstrate the dependence of the 
microbial resistance on the climatic conditions of the 
Republic of Moldova.
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